Abstract
Urticarial vasculitis (UV) is a clinical entity characterized by the aspects of leukocytoclastic vasculitis (LCV). Since its clinical features often overlap with those of common urticaria, a lesional skin biopsy is often necessary for the diagnosis. UV may be idiopathic or caused by endogenous (tumors) or exogenous (infections) factors. UV is frequently associated to consumption of serum complement factors. In this case, UV is called hypocomplementemic urticarial vasculitis (HUV). Hypocomplementemic urticarial vasculitis syndrome (HUVS) is a more severe form characterized by hypocomplementemia and systemic symptoms. Some patients may have UV with normal complement levels (normocomplementemic UV: NUV) and they usually have minimal or no systemic involvement. Response of UV to treatment is variable.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- UV:
-
urticarial vasculitis
- LCV:
-
leukocytoclastic vasculitis
- HUVS:
-
hypocomplementemic urticarial vasculitis syndrome
- SLE:
-
systemic lupus erythematosus
- NUV/HUV:
-
normocomplementemic/hypocomplementemic urticarial vasculitis
- CU:
-
chronic urticaria
- COPD:
-
chronic obstructive pulmonary disease
- ESR:
-
erythrocytes sedimentation rate
- ANA:
-
antinuclear antibodies
- CAPS:
-
cryopyrin-associated periodic syndromes
- FCAS:
-
familial cold autoinflammatory syndrome
- MWS:
-
Muckle-Wells syndrome
- CINCA:
-
chronic infantile neurological cutaneous and articular syndromes
- NLRP3:
-
NOD-like receptor protein 3
References
Venzor J, Lee WL, Huston DP (2002) Urticarial vasculitis. Clin Rev Allergy Immunol 23:201–216
Davis MDP, Brewer JD (2004) Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome. Immunol Allergy Clin North Am 24:183–213
Kolkhir P, Pogorelov D, Olisova O et al (2016) Comorbidity and pathogenic links of chronic spontaneous urticaria and systemic lupus erythematosus – a systematic review. Clin Exp Allergy 46:275–287
Schwartz HR, McDuffie FC, Black LF et al (1982) Hypocomplementemic urticarial vasculitis: association with chronic obstructive pulmonary disease. Mayo Clin Proc 57:231–238
Renard M, Wounters C, Proesmans W (1998) Rapidly progressive glomerulonephritis in a boy with hypocomplementemic urticarial vasculitis. Eur J Pediatr 157:243–245
Balsam L, Karim M, Miller F et al (2008) Crescentic glomerulonephritis associated with hypocomplementemic urticarial vasculitis syndrome. Am J Kidney Dis 52:1168–1173
Black AK (1999) Urticarial vasculitis. Clin Dermatol 17:565–569
Chen HJL, Bloch KJ (2001) Hypocomplementemic urticarial vasculitis, Jaccoud’s arthropathy, valvular heart disease and reversible tracheal stenosis: a surfeit of syndromes. J Rheumatol 28:383–386
Babajanians A, Chung-Park M, Wisnieski JJ (1991) Recurrent pericarditis and cardiac tamponade in a patient with hypocomplementemic urticarial vasculitis syndrome. J Rheumatol 18:752–755
Kervarrec T, Binois R, Bléchet C et al (2015) Hypocomplementaemic urticarial vasculitis with bullous lesions and pericardial involvement. Ann Dermatol Venereol 19:1–6
Hunt DPJ, Weil R, Nicholson AG et al (2006) Pulmonary capillaritis and its relationship to development of emphysema in hypocomplementaemic urticarial vasculitis syndrome. Sarcoidosis Vasc Diffuse Lung Dis 23:70–72
Pujara AC, Mohammed TL (2012) Hypocomplementemic urticarial vasculitis syndrome: a rare cause of basilar panacinar emphysema. J Thorac Imaging 27:W50–W51
Jamison SC, Brierre S, Sweet J et al (2008) A case of precocious emphysema and lung cancer in a woman with a history of hypocomplementemic urticarial vasculitis. Chest 133:787–789
Sjöwall C, Hallbeck M, Sandström P (2015) Clinically suspected recurrence of gastric carcinoid proved to be hypocomplementaemic urticarial vasculitis syndrome with pulmonary involvement. Scand J Rheumatol 44:337–339
Marzano AV, Tavecchio S, Venturini M et al (2015) Urticarial vasculitis and urticarial autoinflammatory syndromes. G Ital Dermatol Venereol 150:41–50
Lee JSS, Loh TH, Seow SC et al (2007) Prolonged urticaria with purpura: the sprectrum of clinical and histopathologic features in a prospective series of 22 patients exhibiting the clinical features of urticarial vasculitis. J Am Accad Dermatol 56:994–1005
Filosto M, Cavallaro T, Pasolini G et al (2009) Idiopathic hypocomplementemic urticarial vasculitis-linked neuropathy. J Neurol Sci 284:179–181
Bock VL, Friedlander M, Waring D et al (2014) Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature. Australas J Dermatol 55:282–285
Moulin C, Debarbieux S, Ducastelle-Lepretre S et al (2010) Urticarial vasculitis and asymptomatic acquired C1 esterase inhibitor deficiency revealing an angioimmunoblastic T cell lymphoma. Eur J Dermatol 20:515–516
Takao M, Hamada T, Kaji T et al (2016) Hypocomplementemic urticarial vasculitis arising in a patient with immunoglobulin G4-related disease. Int J Dermatol 55:430–433
Koudoukpo C, Jachiet M, Zini JM et al (2014) Urticarial vasculitis associated with essential thrombocythaemia progressing to myelofibrosis. Ann Dermatol Venereol 141:773–776
Zuberbier T, Maurer M (2014) Urticarial vasculitis and Schnitzler syndrome. Immunol Allergy Clin North Am 34:141–147
Makol A, Gibson LE, Michet CJ (2012) Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol 18:92–95
Greenberger PA (2014) Chronic urticaria: new management options. World Allergy Organ J 7:31–36
Swaminath A, Magro CM, Dwyer E (2011) Refractory urticarial vasculitis as a complication of ulcerative colitis successfully treated with rituximab. J Clin Rheumatol 17:281–283
Saigal K, Valencia IC, Cohen J et al (2003) Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab. J Am Acad Dermatol 49:S283–S285
Maurer M, Rosen K, Hsie H-J et al (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368:924–935
Sussman G, Hébert J, Barron C et al (2014) Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol 112:170–174
Kai AC, Flohr C, Grattan CE (2014) Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis. Clin Exp Dermatol 39:651–652
Ghazanfar MN, Thomsen SF (2015) Omalizumab for urticarial vasculitis: case report and review of the literature. Case Rep Dermatol Med 2015:1. doi:10.1155/2015/576893
Krause K, Mahamed A, Weller K et al (2015) Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study. J Allergy Clin Immunol 132:751–754
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
De Feo, G., Parente, R., Cardamone, C., Triggiani, M. (2016). Urticarial Vasculitis. A Review of the Literature. In: Dammacco, F., Ribatti, D., Vacca, A. (eds) Systemic Vasculitides: Current Status and Perspectives. Springer, Cham. https://doi.org/10.1007/978-3-319-40136-2_28
Download citation
DOI: https://doi.org/10.1007/978-3-319-40136-2_28
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-40134-8
Online ISBN: 978-3-319-40136-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)